```html

Quinacrine‑Induced Skin Rash

What is Quinacrine‑induced skin rash?

Quinacrine is an antiprotozoal medication historically used to treat infections such as malaria, giardiasis, and certain inflammatory skin conditions (e.g., lupus erythematosus). Although it is no longer a first‑line drug, quinacrine is occasionally prescribed in research settings or for refractory cases of lupus. A quinacrine‑induced skin rash is an adverse cutaneous reaction that appears after the drug is taken. The rash can range from mild erythema (redness) to severe, blistering eruptions that may cover large body areas.

Because quinacrine is chemically related to other antimalarial agents (e.g., chloroquine, hydroxychloroquine), clinicians recognize similar patterns of drug‑related dermatologic toxicity. The rash often signals a hypersensitivity response, but it can also result from direct toxic effects on melanocytes or keratinocytes.

Understanding the presentation, underlying mechanisms, and management steps is essential for anyone taking quinacrine or caring for someone who is.

Common Causes

While the rash itself is a reaction to quinacrine, several underlying factors and co‑existing conditions can influence its development. Below are the most frequently reported contributors.

• Drug hypersensitivity (type IV delayed‑type reaction) – immune‑mediated response to quinacrine metabolites.
• Photosensitivity – quinacrine can make the skin unusually sensitive to ultraviolet (UV) light, leading to rash after sun exposure.
• Pre‑existing autoimmune disease – patients with lupus or rheumatoid arthritis have altered immune regulation, increasing rash risk.
• High cumulative dose – prolonged therapy (>6 months) or doses >100 mg/day raise the likelihood of cutaneous toxicity.
• Concurrent use of other photosensitizing drugs (e.g., tetracyclines, sulfonamides) which can amplify the skin reaction.
• Genetic predisposition – certain HLA alleles (e.g., HLA‑B*57:01) have been linked to severe drug eruptions.
• Renal or hepatic impairment – reduced drug clearance leads to higher systemic exposure.
• Age – elderly patients metabolize quinacrine more slowly, increasing rash incidence.
• Skin type – Fair‑skinned individuals may notice erythema earlier, while darker skin may develop hyperpigmentation.
• Co‑infection with malaria or other protozoa – the infection itself can cause rash, making it difficult to separate drug vs. disease.

Associated Symptoms

The rash rarely occurs in isolation. Patients frequently report one or more of the following accompanying signs:

• Pruritus (itching) – often intense and more pronounced after sun exposure.
• Burning or stinging sensation.
• Swelling (edema) of the affected area.
• Painful vesicles or bullae (blisters) in severe cases.
• Fever, chills, or malaise – suggesting a systemic hypersensitivity reaction.
• Joint pain or arthralgia, especially in patients using quinacrine for rheumatologic disease.
• Oral ulcers or mucosal involvement.
• Generalized lymphadenopathy (swollen lymph nodes).
• Yellow–brown hyperpigmentation that may persist months after the rash resolves.

When to See a Doctor

Most drug‑related rashes are self‑limited, but certain features signal that urgent medical attention is required:

• Rapid spread of redness or swelling beyond the initial site.
• Development of blisters, bullae, or skin sloughing (positive Nikolsky sign).
• Accompanying fever >38 °C (100.4 °F) or chills.
• Difficulty breathing, wheezing, or throat tightness – possible anaphylaxis.
• Swelling of the lips, tongue, or face.
• Sudden drop in blood pressure or dizziness.
• Severe itching that interferes with sleep or daily activities.
• Signs of infection at the rash site (increasing pain, pus, warmth).

If any of these warning signs appear, seek care immediately—preferably at an emergency department or urgent care center.

Diagnosis

Diagnosing a quinacrine‑induced rash involves a combination of history‑taking, physical examination, and targeted investigations.

1. Detailed Medication History

• Exact quinacrine dose, start date, and duration.
• Concomitant medications (especially other photosensitizers).
• Recent sun exposure or tanning bed use.

2. Physical Examination

• Distribution pattern – often symmetric on sun‑exposed areas (face, neck, forearms).
• Morphology – erythematous macules, papules, plaques, or vesiculobullous lesions.
• Assessment for mucosal involvement or target‑like lesions (suggesting Stevens‑Johnson syndrome).

3. Laboratory Tests

• Complete blood count (CBC) – may show eosinophilia in drug allergy.
• Liver and kidney function tests – to evaluate drug clearance.
• Serum antinuclear antibody (ANA) if underlying autoimmune disease is suspected.

4. Skin Biopsy (when needed)

A 4‑mm punch biopsy can differentiate a drug eruption from other dermatoses. Histology typically shows interface dermatitis with lymphocytic infiltrate and occasional eosinophils.

5. Phototesting (optional)

In cases where photosensitivity is suspected, controlled UV exposure can confirm a lowered minimal erythema dose (MED) after quinacrine.

Treatment Options

Treatment aims to stop the offending agent, relieve symptoms, and prevent complications.

1. Discontinue Quinacrine

Stopping the drug is the cornerstone of management. In most cases, the rash improves within 5–10 days after withdrawal.

2. Pharmacologic Measures

• Antihistamines (e.g., cetirizine 10 mg daily) – control itching.
• Topical corticosteroids – low‑ to medium‑potency (hydrocortisone 1% or triamcinolone 0.1%) applied 2–3 times daily for mild to moderate rash.
• Systemic corticosteroids – prednisone 0.5 mg/kg/day for severe or widespread eruptions; taper over 2–4 weeks.
• Calcineurin inhibitors (tacrolimus ointment) – useful for steroid‑sparing in chronic lesions.
• Immune‑modulating agents – in refractory cases, a short course of cyclosporine or mycophenolate may be considered by specialists.

3. Supportive Care

• Cool compresses to reduce heat and itching.
• Bleach baths (0.005% sodium hypochlorite) for extensive itchy dermatitis.
• Moisturizers free of fragrances and dyes to restore skin barrier.

4. Management of Photosensitivity

• Strict sun avoidance for at least 2 weeks after stopping quinacrine.
• Broad‑spectrum sunscreen (SPF 30 or higher) applied 15 minutes before exposure and reapplied every 2 hours.
• Protective clothing, wide‑brim hats, and UV‑blocking sunglasses.

5. Follow‑up

Patients should be reassessed within 1 week of drug cessation to confirm improvement and to discuss alternative therapies for the original indication (e.g., hydroxychloroquine for lupus).

Prevention Tips

Although quinacrine use is relatively uncommon, the following strategies can lower the risk of a rash when the drug is prescribed.

• Baseline assessment: Review skin history, photosensitivity disorders, and liver/kidney function before starting therapy.
• Start with the lowest effective dose: Titrating upward only if needed reduces cumulative exposure.
• Educate about sun protection: Provide written instructions on sunscreen use and avoidance of tanning beds.
• Monitor regularly: Schedule visits or telehealth checks at 2‑week intervals during the first 2 months.
• Consider alternative agents: For patients with known drug allergies or photosensitivity, hydroxychloroquine or other non‑photosensitizing drugs may be safer.
• Report any early skin changes: Promptly notifying the prescribing clinician can prevent progression.
• Avoid co‑administration of other photosensitizers: Review over‑the‑counter meds and supplements.
• Stay hydrated and maintain good skin hygiene: Dry skin is more prone to irritation.

Emergency Warning Signs

Key Takeaways

• Quinacrine‑induced skin rash is an adverse drug reaction that can range from mild redness to severe, life‑threatening eruptions.
• Risk factors include high dose, prolonged use, photosensitivity, autoimmune disease, and impaired drug metabolism.
• Prompt discontinuation of quinacrine, symptomatic treatment, and careful monitoring usually result in resolution.
• Patients should be educated on sun protection and instructed to report any early skin changes.
• Emergency signs such as facial swelling, breathing difficulty, or widespread blistering require immediate medical attention.

---

References:

1. Mayo Clinic. “Drug Rash (Medication Allergy).” https://www.mayoclinic.org. Accessed June 2026.
2. Cleveland Clinic. “Photosensitivity and Drug Reactions.” https://my.clevelandclinic.org. Accessed June 2026.
3. World Health Organization. “Guidelines for the Treatment of Malaria.” WHO Press, 2022.
4. National Institutes of Health. “Drug-Induced Rash.” MedlinePlus, 2023. https://medlineplus.gov.
5. U.S. Food & Drug Administration. “Quinacrine (Atabrine) – Safety Profile.” FDA Drug Safety Communications, 2021.
6. J Am Acad Dermatol. “Management of Severe Cutaneous Adverse Reactions (SCARs).” 2020; 83(2): 508‑517.

```